BioCentury | May 9, 2020
Translation in Brief

Antigens for COVID-19 serological testing; plus mapping glycans on SARS-CoV-2 spike, tumor sampling method and therapy for Parkinson’s

SARS-CoV-2 antigens beyond the spike protein  Described in a medRxiv preprint, researchers from the University of Hong Kong identified SARS-CoV-2 antigens beyond the spike protein that could be used to detect antibodies at early time...
BioCentury | Apr 11, 2020
Emerging Company Profile

Clover: trimerizing fusion proteins

Clover is developing trimerized fusion proteins to target cancer and infectious disease pathways that depend on trimer formation. The company has exclusive, worldwide rights to its Trimer-Tag platform from GenHunter Corp., which was co-founded by...
BioCentury | Apr 9, 2020
Product Development

April 8 COVID-19 roundup: National Academy of Sciences says COVID-19 could continue through summer; plus HHS, SAb-CSL, Vanda-UIC, Avacta-Cytiva and more

As companies and academic groups continue to form new partnerships and identify new drug targets to combat COVID-19, a National Academy of Sciences committee has warned there’s no guarantee the pandemic will be completely contained...
BioCentury | Feb 25, 2020
Product Development

Europe ramps up response to COVID-19 outbreak

With a call for proposals by the Innovative Medicines Initiative for COVID-19 development programs and a new vaccine development consortium led by a Denmark-based biotech, Europe is ramping up its response to the coronavirus outbreak....
BioCentury | Feb 13, 2020
Emerging Company Profile

Pneumagen: out-competing viral sugar binding to prevent infection

With its platform of carbohydrate-binding proteins, Pneumagen is co-opting a pathogenic tool for interacting with host cells to block infections and adapting the technology for use against cancer. Both viruses and bacteria can interact with...
BioCentury | Feb 8, 2020
Tools & Techniques

Beyond PROTACs and the proteasome: broadening the TAC toolbox

The idea of sending disease-driving proteins to the cell’s garbage can is only the first act in a field that now centers around targeted degradation. In the sequel, researchers are extending the principle to other...
BioCentury | Jan 4, 2020
Targets & Mechanisms

SIGLECs go from homing beacons to next-generation checkpoints

Propelled by growing understanding of their biology, and an expression pattern that goes well beyond T cells, SIGLEC proteins are rising as the next set of checkpoint targets to challenge PD-1. The sugar-binding proteins could...
BC Innovations | Dec 5, 2019
Emerging Company Profile

VaxNewMo: bioconjugating antibacterial vaccines

VaxNewMo is developing a bioengineered platform that could yield inexpensive glyconjugate vaccines that prevent bacterial infections, including those not yet covered by existing vaccines. Traditional chemical glycoconjugation is laborious and expensive, as it typically involves...
BC Extra | Aug 13, 2019
Clinical News

Two Ebola therapies best ZMapp in Congo trial

All patients in an Ebola trial in the Democratic Republic of the Congo will be offered treatments from Regeneron and NIAID after they were shown to be superior to ZMapp in preventing death in the...
BC Extra | Aug 7, 2019
Financial News

Glycomine looks toward clinic with Novo-led $33M round

Glycomine raised a tranched $33 million series B round to take its lead rare congenital disease therapy into the clinic. Novo Holdings A/S led the round. Additional new investors Asahi Kasei Pharma Corp. and Mission...
Items per page:
1 - 10 of 126